S&P 500   4,293.93
DOW   33,833.61
QQQ   353.15
High Dividend REITs: Are They an Ideal Way to Diversify?
The single greatest medical breakthrough of all time? (Ad)
Stock market today: Asian shares mostly rise, lifted by bull market on Wall Street
2 Dow Stocks Trading Less Than 10x Earnings are Blue Chip Values
Lithium Has Boomed And This American Stock Is Ready.. (Ad)
Boost for homebuyers: Average long-term US mortgage rate eases from 7-month high to 6.71% this week
6 Best Online and Direct Marketing Retail Stocks to Invest in
The single greatest medical breakthrough of all time? (Ad)
Homebuilding Stocks Defying Cooling Housing Market: Time to Sell?
US applications for jobless benefits highest since October 2021
S&P 500   4,293.93
DOW   33,833.61
QQQ   353.15
High Dividend REITs: Are They an Ideal Way to Diversify?
The single greatest medical breakthrough of all time? (Ad)
Stock market today: Asian shares mostly rise, lifted by bull market on Wall Street
2 Dow Stocks Trading Less Than 10x Earnings are Blue Chip Values
Lithium Has Boomed And This American Stock Is Ready.. (Ad)
Boost for homebuyers: Average long-term US mortgage rate eases from 7-month high to 6.71% this week
6 Best Online and Direct Marketing Retail Stocks to Invest in
The single greatest medical breakthrough of all time? (Ad)
Homebuilding Stocks Defying Cooling Housing Market: Time to Sell?
US applications for jobless benefits highest since October 2021
S&P 500   4,293.93
DOW   33,833.61
QQQ   353.15
High Dividend REITs: Are They an Ideal Way to Diversify?
The single greatest medical breakthrough of all time? (Ad)
Stock market today: Asian shares mostly rise, lifted by bull market on Wall Street
2 Dow Stocks Trading Less Than 10x Earnings are Blue Chip Values
Lithium Has Boomed And This American Stock Is Ready.. (Ad)
Boost for homebuyers: Average long-term US mortgage rate eases from 7-month high to 6.71% this week
6 Best Online and Direct Marketing Retail Stocks to Invest in
The single greatest medical breakthrough of all time? (Ad)
Homebuilding Stocks Defying Cooling Housing Market: Time to Sell?
US applications for jobless benefits highest since October 2021
S&P 500   4,293.93
DOW   33,833.61
QQQ   353.15
High Dividend REITs: Are They an Ideal Way to Diversify?
The single greatest medical breakthrough of all time? (Ad)
Stock market today: Asian shares mostly rise, lifted by bull market on Wall Street
2 Dow Stocks Trading Less Than 10x Earnings are Blue Chip Values
Lithium Has Boomed And This American Stock Is Ready.. (Ad)
Boost for homebuyers: Average long-term US mortgage rate eases from 7-month high to 6.71% this week
6 Best Online and Direct Marketing Retail Stocks to Invest in
The single greatest medical breakthrough of all time? (Ad)
Homebuilding Stocks Defying Cooling Housing Market: Time to Sell?
US applications for jobless benefits highest since October 2021
NYSE:GKOS

Glaukos (GKOS) Stock Forecast, Price & News

$68.26
+1.71 (+2.57%)
(As of 06/8/2023 ET)
Compare
Today's Range
$65.52
$70.05
50-Day Range
$45.44
$68.26
52-Week Range
$40.45
$70.05
Volume
809,275 shs
Average Volume
421,540 shs
Market Capitalization
$3.29 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$61.67

Glaukos MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
9.7% Downside
$61.67 Price Target
Short Interest
Bearish
11.89% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.90
Upright™ Environmental Score
News Sentiment
0.25mentions of Glaukos in the last 14 days
Based on 25 Articles This Week
Insider Trading
Selling Shares
$2.10 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.30) to ($1.84) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.45 out of 5 stars

Medical Sector

916th out of 986 stocks

Surgical & Medical Instruments Industry

89th out of 97 stocks


GKOS stock logo

About Glaukos (NYSE:GKOS) Stock

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in San Clemente, CA.

Receive GKOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Glaukos and its competitors with MarketBeat's FREE daily newsletter.

GKOS Stock News Headlines

4 big analyst picks: Wall Street extols Amazon
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser
Small cap wins $1.65 billion contract to make them. GlobeNewswire says this is a $51.1 Billion market by 2026. See why this stock could soar 2,476% >>>
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
Glaukos (NYSE:GKOS) Raised to Overweight at Piper Sandler
Analyst Expectations for Glaukos's Future
Glaukos (NYSE:GKOS) Price Target Raised to $63.00
Glaukos (NYSE:GKOS) Rating Lowered to Sell at StockNews.com
Glaukos Co. (NYSE:GKOS) CEO Sells $701,702.54 in Stock
Glaukos Co. (NYSE:GKOS) CEO Sells $222,277.04 in Stock
888 Reiterates Maintains Rating for Glaukos (NYSE:GKOS)
See More Headlines

GKOS Price History

GKOS Company Calendar

Last Earnings
5/03/2023
Today
6/08/2023
Next Earnings (Estimated)
8/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Employees
727
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$61.67
High Stock Price Forecast
$80.00
Low Stock Price Forecast
$48.00
Forecasted Upside/Downside
-9.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
9 Analysts

Profitability

Net Income
$-99,190,000.00
Pretax Margin
-47.86%

Debt

Sales & Book Value

Annual Sales
$282.86 million
Book Value
$11.11 per share

Miscellaneous

Free Float
44,449,000
Market Cap
$3.29 billion
Optionable
Optionable
Beta
1.23

Key Executives

  • Thomas William Burns
    Chairman & Chief Executive Officer
  • Joseph E. GilliamJoseph E. Gilliam
    President & Chief Operating Officer
  • Alex Thurman
    Chief Financial Officer & Senior Vice President
  • Jay L. Katz
    Chief Medical Officer
  • Diane W. Biagianti
    Senior Vice President & General Counsel













GKOS Stock - Frequently Asked Questions

Should I buy or sell Glaukos stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Glaukos in the last twelve months. There are currently 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GKOS shares.
View GKOS analyst ratings
or view top-rated stocks.

What is Glaukos' stock price forecast for 2023?

9 equities research analysts have issued 12 month price targets for Glaukos' shares. Their GKOS share price forecasts range from $48.00 to $80.00. On average, they predict the company's share price to reach $61.67 in the next year. This suggests that the stock has a possible downside of 9.7%.
View analysts price targets for GKOS
or view top-rated stocks among Wall Street analysts.

How have GKOS shares performed in 2023?

Glaukos' stock was trading at $43.68 at the start of the year. Since then, GKOS shares have increased by 56.3% and is now trading at $68.26.
View the best growth stocks for 2023 here
.

Are investors shorting Glaukos?

Glaukos saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 5,480,000 shares, an increase of 7.7% from the April 30th total of 5,090,000 shares. Based on an average trading volume of 408,400 shares, the days-to-cover ratio is currently 13.4 days. Approximately 11.9% of the company's stock are sold short.
View Glaukos' Short Interest
.

When is Glaukos' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our GKOS earnings forecast
.

How were Glaukos' earnings last quarter?

Glaukos Co. (NYSE:GKOS) issued its earnings results on Wednesday, May, 3rd. The medical instruments supplier reported ($0.59) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.61) by $0.02. The medical instruments supplier earned $73.90 million during the quarter, compared to the consensus estimate of $67.74 million. Glaukos had a negative trailing twelve-month return on equity of 21.20% and a negative net margin of 48.15%. Glaukos's revenue was up 9.2% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.38) EPS.

What guidance has Glaukos issued on next quarter's earnings?

Glaukos issued an update on its FY 2023 earnings guidance on Wednesday, May, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $295.00 million-$300.00 million, compared to the consensus revenue estimate of $293.53 million.

What is Thomas W. Burns' approval rating as Glaukos' CEO?

10 employees have rated Glaukos Chief Executive Officer Thomas W. Burns on Glassdoor.com. Thomas W. Burns has an approval rating of 100% among the company's employees. This puts Thomas W. Burns in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Glaukos own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Glaukos investors own include NVIDIA (NVDA), Marvell Technology (MRVL), PTC Therapeutics (PTCT), PayPal (PYPL), QUALCOMM (QCOM), Alibaba Group (BABA), Teladoc Health (TDOC), Intel (INTC), Advanced Micro Devices (AMD) and Boeing (BA).

When did Glaukos IPO?

(GKOS) raised $76 million in an initial public offering (IPO) on Thursday, June 25th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs served as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers.

What is Glaukos' stock symbol?

Glaukos trades on the New York Stock Exchange (NYSE) under the ticker symbol "GKOS."

Who are Glaukos' major shareholders?

Glaukos' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (9.72%), Brown Capital Management LLC (6.03%), Artisan Partners Limited Partnership (3.89%), Braidwell LP (3.75%), State Street Corp (3.63%) and Fred Alger Management LLC (3.15%). Insiders that own company stock include Gilbert H Kliman, Joseph E Gilliam, Thomas William Burns and William J Phd Link.
View institutional ownership trends
.

How do I buy shares of Glaukos?

Shares of GKOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Glaukos' stock price today?

One share of GKOS stock can currently be purchased for approximately $68.26.

How much money does Glaukos make?

Glaukos (NYSE:GKOS) has a market capitalization of $3.29 billion and generates $282.86 million in revenue each year. The medical instruments supplier earns $-99,190,000.00 in net income (profit) each year or ($2.92) on an earnings per share basis.

How many employees does Glaukos have?

The company employs 727 workers across the globe.

How can I contact Glaukos?

Glaukos' mailing address is 229 AVENIDA FABRICANTE, SAN CLEMENTE CA, 92672. The official website for the company is www.glaukos.com. The medical instruments supplier can be reached via phone at (949) 367-9600, via email at investors@glaukos.com, or via fax at 949-367-9984.

This page (NYSE:GKOS) was last updated on 6/9/2023 by MarketBeat.com Staff

My Account -